Get the Stockscreener App
22.22
0.09%
-0.02
After Hours:
22.14
-0.08
-0.36%
Pharvaris Nv stock is traded at $22.22, with a volume of 130.41K.
It is down -0.09% in the last 24 hours and down -10.94% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$22.24
Open:
$22.26
24h Volume:
130.41K
Relative Volume:
0.70
Market Cap:
$1.43B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-7.8694
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-3.35%
1M Performance:
-10.94%
6M Performance:
+20.24%
1Y Performance:
-10.66%
1-Day Range:
$21.76
$22.40
1-Week Range:
$21.76
$23.64
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
22.22 | 1.43B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Can Pharvaris N.V. stock deliver sustainable ROEJuly 2025 Price Swings & AI Based Buy and Sell Signals - newser.com
Is Pharvaris N.V. stock safe for conservative investorsJuly 2025 Earnings & Weekly Chart Analysis and Guides - newser.com
Technical signs of recovery in Pharvaris N.V.CPI Data & Fast Gaining Stock Strategy Reports - newser.com
Will Pharvaris N.V. stock attract ESG investors2025 Price Targets & Smart Allocation Stock Reports - newser.com
Can Pharvaris N.V. (9EN) stock deliver strong annual returnsM&A Rumor & Fast Exit Strategy with Risk Control - newser.com
How forex fluctuations impact Pharvaris N.V. (9EN) stockBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Is Pharvaris N.V. (9EN) stock undervalued after correctionQuarterly Portfolio Summary & Long-Term Safe Investment Plans - newser.com
Visual analytics tools that track Pharvaris N.V. performance2025 Macro Impact & Daily Volume Surge Signals - newser.com
How Pharvaris N.V. stock compares to market leaders2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
What recovery options are there for Pharvaris N.V.Weekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Can Pharvaris N.V. (9EN) stock reach $200 price target2025 Short Interest & Capital Efficiency Focused Ideas - newser.com
How sentiment analysis helps forecast Pharvaris N.V.Layoff News & Real-Time Volume Analysis Alerts - newser.com
Full technical analysis of Pharvaris N.V. stockLong Setup & Weekly Setup with ROI Potential - newser.com
Will earnings trigger a reversal in Pharvaris N.V.Insider Selling & Low Risk High Win Rate Stock Picks - newser.com
Institutional Investors May Adopt Severe Steps After Pharvaris N.V.'s (NASDAQ:PHVS) Latest 3.4% Drop Adds to a Year Losses - 富途牛牛
How interest rate cuts could boost Pharvaris N.V. stockJuly 2025 Highlights & High Accuracy Investment Signals - Fundação Cultural do Pará
How Pharvaris N.V. (9EN) stock trades in high volatility2025 Macro Impact & AI Enhanced Trading Alerts - newser.com
Why Pharvaris N.V. stock is favored by pension fundsTrade Exit Report & Precise Swing Trade Alerts - Fundação Cultural do Pará
Pharvaris (NASDAQ:PHVS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):